It is quite disturbing to discover that you are the one who is making acerebral argument about "missied earnings and revenue..." It is so much more than that to evaluate the stock price, especially for pharmaceutical companies like GSK. It is funny how you make dumb argument and accuse others as lacking brain at the same time.... Amuzing.
Lack of revenue and earnings? It made tons of cash. More importantly, GSK has very robust late stage pipelines, better than the most big pharmas. The chart tells me it is oversold and it may have found the bottom when it hit $36 range. It shows it could hit $38.75, which is next major resistance. If it clears that resistance, it will hit $40+.